Navigation Links
Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint

DUBLIN, Ohio--(BUSINESS WIRE)--Jun 20, 2007 - Neoprobe Corporation (OTCBB:NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced positive preliminary results from a multicenter Phase 2 clinical study of its lead clinical candidate, Lymphoseek(R) (Technetium Tc99m DTPA-mannosyl-dextran). Lymphoseek is a proprietary radioactive targeting agent being developed for use with handheld gamma detection devices, such as Neoprobe's neo2000(R) system, in a surgical procedure known as Sentinel Lymph Node Biopsy (SLNB). The primary endpoint of this multicenter, single-arm, open-label, within-patient, single-dose, multi-stage trial measured the rate at which Lymphoseek localized to lymphoid tissue with a goal of achieving 90% localization. In results reported today, localization of Lymphoseek to lymphoid tissue was observed in over 94% of the SLNB procedures performed as a part of the Phase 2 trial in patients with either breast cancer or melanoma.

This study is being conducted at five of the leading cancer centers in the U.S.: John Wayne Cancer Center; M.D. Anderson, the University of California, San Francisco; University Hospitals - Cleveland (Case Western Reserve); and the University of Louisville. Positive interim results from the trial were announced earlier this year. Neoprobe also reported that no drug-related significant adverse events have been noted in results analyzed to-date. Neoprobe now plans to begin winding down Phase 2 trial activities, collecting the required 30-day patient safety follow-up information and accumulating data to report to FDA. In parallel, Neoprobe is also preparing to submit its Phase 3 pivotal trial protocol to FDA.

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Neoprobe Phase Lymphoseek Trial Meets Primary Endpoint
(Date:1/15/2014)... AARP Foundation today announced it has established a ... severe cold weather that has gripped much of the nation. ... need; so to support these emergency relief efforts AARP and ... could mean up to $500,000 in aid. The matching program ...
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: SHP, ... Office of Fair Trading (OFT) approval condition to the announced tender ... VPHM).   As a result of the waiver, the ... to complete the tender offer on January 24, 2014 following the ...
(Date:1/15/2014)... 2014  In an unprecedented effort to curb the spread of "superbugs" ... transport vehicles, an advanced and portable UV germicidal lamp manufactured by ... time. In order to prevent EMS paramedics and ... West Palm Beach Fire Rescue is the first ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2
... 2011 Generex Biotechnology Corporation (OTCBB: GNBT) ( ... subsidiary Antigen Express, Inc. ( www.antigenexpress.com ) presented ... with an off-the-shelf immunotherapeutic cancer vaccine, AE37, in ... Sixth Annual ImVacS: The Immunotherapeutics and Vaccine Summit ...
... Inc. (Nasdaq: REGN ) today announced that clinical ... will be presented at the upcoming American Society of Retina ... 22, 2011 in Boston, Massachusetts. The presentations ... Phase 3 VIEW 1 and VIEW 2 Studies Comparing VEGF ...
Cached Medicine Technology:Generex Subsidiary Antigen Express Provides Update on Phase 2 Breast Cancer Immunotherapy Program 2Generex Subsidiary Antigen Express Provides Update on Phase 2 Breast Cancer Immunotherapy Program 3Generex Subsidiary Antigen Express Provides Update on Phase 2 Breast Cancer Immunotherapy Program 4Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting 2Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting 3
(Date:4/23/2014)... National Institute of Arthritis and Musculoskeletal and Skin Diseases ... Ross Prize in Molecular Medicine, conferred by the Feinstein ... award will be given on June 9 at the ... scientific presentations by Dr. O,Shea and other prominent researchers. ... , The award, which includes a $50,000 prize from ...
(Date:4/23/2014)... LAFAYETTE, Ind. - Purdue University researchers have developed a ... living cell by using tiny gold particles with tails ... professor of agricultural and biological engineering, used gold nanoparticles ... known as BRCA1 messenger RNA splice variants, which can ... number of these mRNA splice variants in a cell ...
(Date:4/23/2014)... testosterone falls below normal levels are more likely to ... heart disease and type 2 diabetes. A new simple ... testing and possible treatment is described in an article ... publication from Mary Ann Liebert, Inc., publishers. The article ... Health website at http://www.liebertpub.com/jmh . ...
(Date:4/23/2014)... As evidence mounts showing the potential health benefits of ... people are taking supplements. And the chemical industry is ... supplements, health effects could deter growth, so the industry ... claims, according to the cover story in Chemical ... of the American Chemical Society. , Melody M. Bomgardner, ...
(Date:4/23/2014)... scientists led by a researcher from the Cancer Science ... of Singapore has identified the cancer specific stem cell ... possibility of developing new drugs for the treatment of ... research group, led by Dr Chan Shing Leng, Research ... time that a cancer-specific variant of a cell surface ...
Breaking Medicine News(10 mins):Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3
... Pediatric Daytime Sleepiness Scale (PDSS) is an independent, reliable ... breathing disorder and daytime sleepiness on a teenagers academic ... 1 issue of the journal SLEEP. , The study, ... in Buenos Aires, Argentina, focused on 2,884 students, whose ...
... VA As the obesity epidemic grows in ... far reaching health concerns for overweight children. Sleep-disordered ... ranging in severity from snoring to obstructive sleep ... and African- American, according to a new study ...
... California,s,stem cell agency is inviting for-profit companies ... the Foundation for Taxpayer and Consumer Rights,(FTCR) noted ... to scrutinize the awards process to prevent abuse., ... has just,issued calls for applications for two types ...
... Association (USGA) awarded a $20,000 matching grant to Marianjoy,Rehabilitation ... and the creation of a golf program at Marianjoy,for ... USGA has supported programs that bring the game,of golf ... Golf Pro,who leads the Winter Therapeutic Golf Clinics at ...
... Front Needs of Families of Fallen Service Members -, ... to the Nevada National Guard Patriots Fund, which will,support families ... Scott Celley, vice president of external affairs at TriWest, ... p.m. on Tuesday, Dec.,4 on the Flightline of the Nevada ...
... of relationships between parents and their adult children improve ... researcher has found. , Karen Fingerman, an associate professor ... Consumer and Family Sciences, examined relationships adults 70 and ... offspring. The parents in the study also suffered either ...
Cached Medicine News:Health News:PDSS reliable in measuring impact of sleep disorders on teens' academic performance 2Health News:Childhood sleep-disordered breathing disproportionately affects obese and African-Americans 2Health News:Close Scrutiny Needed as First Stem Cell Grants Offered to For-Profit Companies, Consumers Say 2Health News:Marianjoy Rehabilitation Hospital Therapeutic Golf Program Receives a $20,000 Matching Grant From the USGA 2Health News:TriWest Contributes $25,000 to Nevada National Guard 2Health News:Aging improves parent, child relationships, research shows 2
... The Kisses tag is part of ... the Hugs system. The Kisses tag ... after it has been bonded with ... baby. he two tags remain electronically ...
The PDC Smart® Key Fob can be programmed on demand using a 13.56 MHz RFID reader/writer and is ideal for long-term use applications such as electronic access control or loyalty programs....
... VeriMed can provide healthcare professionals witha ... or shecant speak, cant remember, oris ... to affected individuals. The application can ... obtain a comparable level of care ...
... component of the Hugs system ... staff in matching infants with ... hospital. With the Kisses ... effective and electronic enhancement to ...
Medicine Products: